 INTRODUCTION
Merck
& Co., Inc. is a global, research-driven pharmaceutical company
that discovers, develops, manufactures and markets a broad range
of human and animal health products, directly and through its
joint ventures, and provides pharmaceutical benefits services.
Merck
& Co., Inc. strategy for growth is to discover important new
medicines through breakthrough research and demonstrate the value
of these medicines to patients, payers and providers.
Merck
Sharp & Dohme (MSD Egypt) have been established in Egypt
as a Scientific Office since 1960. From 1960 until 1984, MSD products
have either been imported through a public sector distribution company
(EGYDRUG), or locally manufactured through a government owned
manufacturer (Al-Kahira Company) and a private sector company
(EIPICO).
Throughout these
years, (MSD Egypt) introduced to Egyptian patients milestone
treatments for various diseases:
1. Methyldopa, the 1st centrally acting anti-hypertensive.
2. Indomethacin, a breakthrough in arthritis
treatment that became the standard to which other molecules compares
to.
3. The 60's also witnessed the introduction
of the diuretic Hydroclorothiazide;, a centrally acting tricyclic
antidepressant (Amitriptyline),
and a new treatment for parkinsonism (Carbidopa/Levodopa).
4. In the 80's, Timolol, the 1st topical
beta-blocker eye drops used for glaucoma treatment, and Norfloxacin,
a quinolone used for urinary tract infections.
Between the years 1994 and 2001, registration and
new product introductions were the primary objectives of our organization.
(MSD Egypt) was able to introduce in the Egyptian market
the following new breakthrough products:
1. Finasteride, the first 5- alpha reductase inhibitor,that
causes regression of (BPH).
2. Imipenem, the 1st thienamycin antibiotic for
treatment of life threatening infections.
3. Simvastatin, a (HMG-CoA) reductase inhibitor
proven to reduce mortality in (CHD) patients with hypercholesterolemia
4. Enalapril, a long acting (ACE) inhibitor
for the treatment of hypertension and heart failure.
5. Losartan, an (A2) antagonist for the
treatment of hypertension.
6. Alendronate, the 1st non-hormonal therapy for
osteoporosis with proven fracture reduction
7. Rofecoxib, the 1st Cox-2 inhibitor available
in Egypt for treatment of osteo-arthritis, pain, and primary dysmenorrhea.
8. Dorzolamide, the 1st topical carbonic
anhydrase inhibitor, a long awaited breakthrough in glaucoma therapy
9. Montelukast, the 1st leukotriene receptor antagonist
for treatment of asthma.
As of January
1st 2000, Global Napi Pharmaceuticals (GNP) became Merck
& Co., Inc., licensee in Egypt. RAMCO, SOFICO PHARM and EGYDRUG
are the distributors of MSD products in Egypt.
Worldwide, Merck
& Co., Inc. markets medicines in 20 therapeutic categories -
the broadest product line in the pharmaceutical industry. Overall,
Merck & Co., Inc. markets more than 100 medicines and vaccines
throughout the world.
Mission
of MSD Egypt :
- Provide Society
with superior products and services to improve the quality of
life and satisfy customer needs.
- Provide our
Employees with meaningful work and professional growth and
development.
This Website
is intended for healthcare professionals only.
The included information is not addressed or intended for the general
public.
|
INTRODUCTION
